Investing.com -- 抗体疗法公司Adagene Inc. (NASDAQ:ADAG)宣布获得赛诺菲(EPA:SASY)高达2500万美元的战略投资并扩大合作关系后,股价上涨6.1%。 此项投资将用于资助Adagene的研发活动,包括通过随机II期临床试验在微卫星稳定型结直肠癌(MSS CRC)中开发抗CTLA-4 SAFEbody药物muzastotug(ADG126)。 作为扩大...
Source LinkInvesting.com -- 抗体疗法公司Adagene Inc. (NASDAQ:ADAG)宣布获得赛诺菲(EPA:SASY)高达2500万美元的战略投资并扩大合作关系后,股价上涨6.1%。 此项投资将用于资助Adagene的研发活动,包括通过随机II期临床试验在微卫星稳定型结直肠癌(MSS CRC)中开发抗CTLA-4 SAFEbody药物muzastotug(ADG126)。 作为扩大...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.